NeuroOne Medical Technologies Q1 2026 Earnings Call Insights
- Sales Growth Projection: NeuroOne projects fiscal 2026 sales to reach at least $10.5 million, reflecting a 17% increase from fiscal 2025, indicating strong confidence in market demand and potential for continued growth.
- Technology Adoption Progress: In Q1 2026, nearly half of all ablations performed since the launch of the OneRF brain ablation system were conducted, demonstrating rapid market acceptance and increasing clinical demand for the technology.
- International Strategy: The company is pursuing ISO 13485 certification as a first step towards international commercialization, which is expected to lay the groundwork for future global market expansion and enhance its competitive position.
- Financial Performance Overview: Product revenue for Q1 2026 was $2.9 million, down from $3.3 million in Q1 2025, but showed a sequential increase of 5.5%, reflecting the company's efforts in cost control and market adaptability.
Trade with 70% Backtested Accuracy
Analyst Views on NMTC
About NMTC
About the author
NeuroOne Medical Technologies Q1 2026 Earnings Call Insights
- Sales Growth Projection: NeuroOne projects fiscal 2026 sales to reach at least $10.5 million, reflecting a 17% increase from fiscal 2025, indicating strong confidence in market demand and potential for continued growth.
- Technology Adoption Progress: In Q1 2026, nearly half of all ablations performed since the launch of the OneRF brain ablation system were conducted, demonstrating rapid market acceptance and increasing clinical demand for the technology.
- International Strategy: The company is pursuing ISO 13485 certification as a first step towards international commercialization, which is expected to lay the groundwork for future global market expansion and enhance its competitive position.
- Financial Performance Overview: Product revenue for Q1 2026 was $2.9 million, down from $3.3 million in Q1 2025, but showed a sequential increase of 5.5%, reflecting the company's efforts in cost control and market adaptability.
NeuroOne Medical Technologies Q1 2026 Earnings Beat Expectations
- Earnings Highlights: NeuroOne Medical Technologies reported a Q1 2026 GAAP EPS of -$0.03, beating expectations by $0.01, indicating potential improvements in profitability despite ongoing losses.
- Revenue Performance: The company generated $2.9 million in revenue for Q1, a 12.1% year-over-year decline, yet it exceeded market expectations by $0.24 million, suggesting a resilient market demand and sales capability amidst challenges.
- Future Targets: NeuroOne aims for at least $10.5 million in revenue for 2026, reflecting the company's confidence in future growth and commitment to advancing its brain and pain therapy platforms.
- Product Commercialization Progress: With a staggering 907% increase in Q4 product revenue, NeuroOne is actively advancing the commercialization of its drug delivery systems, indicating strategic success in innovative product development and market outreach.
TELO, PCSA, RVPH, NMTC, BRTX Experience After-Hours Trading Surge Amid Limited News and Specific Updates
Biotech Stock Gains: Small-cap biotech stocks TELO, PCSA, RVPH, NMTC, and BRTX experienced significant after-hours gains driven by speculative trading and company updates, despite the absence of new disclosures.
Telomir Pharmaceuticals (TELO): TELO shares surged 43% after-hours, attributed to renewed interest in its in vitro data showcasing Telomir-1's unique targeting capabilities in cancer therapies.
Processa Pharmaceuticals (PCSA): PCSA shares rose 32.6% in after-hours trading, continuing a rally from the regular session, with no recent official news or updates from the company.
NeuroOne Medical Technologies (NMTC): NMTC shares increased 9.5% after announcing a 163% rise in preliminary product revenue for fiscal year 2025, alongside an upcoming virtual webinar, which sparked investor interest.
Biotech Stocks Recover in After-Hours Trading Driven by Positive Sector Trends
Biotech Stocks Performance: Biotech stocks experienced strong after-hours gains, with notable rebounds from small-cap companies like Ovid Therapeutics, NeuroOne Medical, and PepGen, driven by positive sentiment following Pfizer's drug price cuts and investment in domestic manufacturing.
Ovid Therapeutics Update: Ovid Therapeutics saw a 7.69% increase in after-hours trading, supported by a recent Buy rating from Lucid Capital and a narrower quarterly loss, alongside a $7 million royalty sale agreement related to future revenues.
PepGen's Recent Surge: PepGen's stock rose 3.03% after-hours, continuing a volatile week with over 120% growth, attributed to positive Phase 2 trial results for its myotonic dystrophy treatment and a successful $100 million public offering.
Reviva Pharmaceuticals and Anika Therapeutics: Reviva Pharmaceuticals gained 5.81% after-hours following a significant intraday surge, while Anika Therapeutics rose 5.53% ahead of its upcoming earnings report, despite a quiet news cycle for both companies.
NeuroOne® Obtains FDA 510(k) Approval for OneRF® Trigeminal Nerve Ablation System to Address Facial Pain
FDA Clearance: NeuroOne Medical Technologies has received FDA clearance for its OneRF® Trigeminal Nerve Ablation System, aimed at treating trigeminal neuralgia through minimally invasive procedures.
Technology Features: The system utilizes a unique multi-contact RF probe to deliver targeted radiofrequency energy, enhancing safety and accuracy while potentially reducing procedural time and improving patient comfort.
Market Potential: This marks NeuroOne's entry into pain management therapies, with plans for a limited commercial launch in late 2025 and opportunities to expand into other neurological disorders and therapeutic applications.
Company Overview: NeuroOne focuses on developing minimally invasive solutions for various neurological conditions, aiming to improve patient outcomes and reduce procedural costs.
NeuroOne Medical Technologies Receives FDA Approval for OneRF Trigeminal Nerve Ablation System
FDA Clearance: NeuroOne Medical Technologies Corporation has received FDA clearance to market its OneRF Trigeminal Nerve Ablation System for creating radiofrequency lesions to treat pain and for functional neurosurgical procedures.
Target Market: The system is aimed at treating trigeminal neuralgia, a chronic facial pain condition affecting around 150,000 people annually in the U.S.
Commercial Launch Plans: The company plans a limited commercial launch of the product in the fourth quarter of this year.
Revenue Potential: NeuroOne anticipates potential revenue generation from trigeminal nerve ablation as early as late calendar year 2025, following discussions with strategic partners.
NeuroOne Medical Technologies Q1 2026 Earnings Call Insights
- Sales Growth Projection: NeuroOne projects fiscal 2026 sales to reach at least $10.5 million, reflecting a 17% increase from fiscal 2025, indicating strong confidence in market demand and potential for continued growth.
- Technology Adoption Progress: In Q1 2026, nearly half of all ablations performed since the launch of the OneRF brain ablation system were conducted, demonstrating rapid market acceptance and increasing clinical demand for the technology.
- International Strategy: The company is pursuing ISO 13485 certification as a first step towards international commercialization, which is expected to lay the groundwork for future global market expansion and enhance its competitive position.
- Financial Performance Overview: Product revenue for Q1 2026 was $2.9 million, down from $3.3 million in Q1 2025, but showed a sequential increase of 5.5%, reflecting the company's efforts in cost control and market adaptability.
NeuroOne Medical Technologies Q1 2026 Earnings Beat Expectations
- Earnings Highlights: NeuroOne Medical Technologies reported a Q1 2026 GAAP EPS of -$0.03, beating expectations by $0.01, indicating potential improvements in profitability despite ongoing losses.
- Revenue Performance: The company generated $2.9 million in revenue for Q1, a 12.1% year-over-year decline, yet it exceeded market expectations by $0.24 million, suggesting a resilient market demand and sales capability amidst challenges.
- Future Targets: NeuroOne aims for at least $10.5 million in revenue for 2026, reflecting the company's confidence in future growth and commitment to advancing its brain and pain therapy platforms.
- Product Commercialization Progress: With a staggering 907% increase in Q4 product revenue, NeuroOne is actively advancing the commercialization of its drug delivery systems, indicating strategic success in innovative product development and market outreach.
TELO, PCSA, RVPH, NMTC, BRTX Experience After-Hours Trading Surge Amid Limited News and Specific Updates
Biotech Stock Gains: Small-cap biotech stocks TELO, PCSA, RVPH, NMTC, and BRTX experienced significant after-hours gains driven by speculative trading and company updates, despite the absence of new disclosures.
Telomir Pharmaceuticals (TELO): TELO shares surged 43% after-hours, attributed to renewed interest in its in vitro data showcasing Telomir-1's unique targeting capabilities in cancer therapies.
Processa Pharmaceuticals (PCSA): PCSA shares rose 32.6% in after-hours trading, continuing a rally from the regular session, with no recent official news or updates from the company.
NeuroOne Medical Technologies (NMTC): NMTC shares increased 9.5% after announcing a 163% rise in preliminary product revenue for fiscal year 2025, alongside an upcoming virtual webinar, which sparked investor interest.
Biotech Stocks Recover in After-Hours Trading Driven by Positive Sector Trends
Biotech Stocks Performance: Biotech stocks experienced strong after-hours gains, with notable rebounds from small-cap companies like Ovid Therapeutics, NeuroOne Medical, and PepGen, driven by positive sentiment following Pfizer's drug price cuts and investment in domestic manufacturing.
Ovid Therapeutics Update: Ovid Therapeutics saw a 7.69% increase in after-hours trading, supported by a recent Buy rating from Lucid Capital and a narrower quarterly loss, alongside a $7 million royalty sale agreement related to future revenues.
PepGen's Recent Surge: PepGen's stock rose 3.03% after-hours, continuing a volatile week with over 120% growth, attributed to positive Phase 2 trial results for its myotonic dystrophy treatment and a successful $100 million public offering.
Reviva Pharmaceuticals and Anika Therapeutics: Reviva Pharmaceuticals gained 5.81% after-hours following a significant intraday surge, while Anika Therapeutics rose 5.53% ahead of its upcoming earnings report, despite a quiet news cycle for both companies.
NeuroOne® Obtains FDA 510(k) Approval for OneRF® Trigeminal Nerve Ablation System to Address Facial Pain
FDA Clearance: NeuroOne Medical Technologies has received FDA clearance for its OneRF® Trigeminal Nerve Ablation System, aimed at treating trigeminal neuralgia through minimally invasive procedures.
Technology Features: The system utilizes a unique multi-contact RF probe to deliver targeted radiofrequency energy, enhancing safety and accuracy while potentially reducing procedural time and improving patient comfort.
Market Potential: This marks NeuroOne's entry into pain management therapies, with plans for a limited commercial launch in late 2025 and opportunities to expand into other neurological disorders and therapeutic applications.
Company Overview: NeuroOne focuses on developing minimally invasive solutions for various neurological conditions, aiming to improve patient outcomes and reduce procedural costs.
NeuroOne Medical Technologies Receives FDA Approval for OneRF Trigeminal Nerve Ablation System
FDA Clearance: NeuroOne Medical Technologies Corporation has received FDA clearance to market its OneRF Trigeminal Nerve Ablation System for creating radiofrequency lesions to treat pain and for functional neurosurgical procedures.
Target Market: The system is aimed at treating trigeminal neuralgia, a chronic facial pain condition affecting around 150,000 people annually in the U.S.
Commercial Launch Plans: The company plans a limited commercial launch of the product in the fourth quarter of this year.
Revenue Potential: NeuroOne anticipates potential revenue generation from trigeminal nerve ablation as early as late calendar year 2025, following discussions with strategic partners.
